Metastatic Pancreatic Ductal Adenocarcinoma research hub
4 indexed studies · 3 currently recruiting
- recruitingPHASE2, PHASE3
A Study to Assess Intravenous (IV) Telisotuzumab Adizutecan in Combination With Fluorouracil, Folinic Acid, and Oxaliplatin (FOLFOX) Compared to Standard of Care in Adult Participants With First-Line Metastatic Pancreatic Ductal Adenocarcinoma
This study looks at a new drug, telisotuzumab adizutecan, combined with standard chemotherapy (FOLFOX) for advanced pancreatic cancer. It compares this combination to the usual treatment to see if it works better and is safe for adults.
United States · Australia · Israel - recruitingPHASE3
Study of Daraxonrasib and Daraxonrasib + GnP as First-line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma
This study is looking at a new drug, daraxonrasib, for people with pancreatic cancer that has spread. It compares daraxonrasib alone, or with standard chemotherapy (gemcitabine and nab-paclitaxel), against standard chemotherapy by itself. The aim is to see if the new treatments can help people live longer and stop the cancer from growing.
United States · Australia · Brazil - recruitingPHASE3
Study of Daraxonrasib (RMC-6236) in Patients With Resected Pancreatic Ductal Adenocarcinoma (PDAC)
This study is for people who have had surgery for pancreatic cancer. We are testing a new drug, daraxonrasib, to see if it can stop the cancer from coming back, compared to just being watched. It's to help see if this new treatment works better.
United States · France · Germany - active not recruitingPHASE3
Phase 3 Study of Daraxonrasib (RMC-6236) in Patients With Previously Treated Metastatic Pancreatic Ductal Adenocarcinoma (PDAC)
This study is looking for a new treatment for pancreatic cancer that has spread. It compares a new medicine called RMC-6236 with standard chemotherapy for people whose cancer has already been treated once before. The aim is to see if the new medicine is safer and works better.
United States · France · Germany